Navigation Links
SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder

Results Expected to be Delivered by November 2007

BARCELONA, Spain, October 9 /PRNewswire/ -- This double-blind, placebo-controlled and multi-center Phase II trial includes 332 patients with Overactive Bladder (OAB) and has been conducted at 77 sites in 11 countries (US, Germany, Spain, The Netherlands, Czech Republic, Hungary, Poland, Russia, South Africa, New Zealand and Australia). The company expects to report the results of this trial during November.

The total study treatment duration after screening and baseline has been 4 weeks. Patients have been randomized into one of five treatment arms, which include one placebo, one active control (Tolterodine, 4 mg once daily) and three SVT-40776 groups (once daily administration). The primary endpoint of the trial is the mean change from baseline to last day of treatment in the number of micturitions per day. The trial will also generate tolerability data.

"The successful completion of patient enrollment in this clinical trial represents an important milestone in the development of SVT-40776" said Jordi Julve, CEO.

"We are very excited to look at the data regarding the efficacy and safety of SVT-40776 and to confirm the excellent profile suggested by our previous clinical data. We expect that SVT-40776 will improve the efficacy/tolerability ratio compared to the current available treatments, being the treatment of choice for patients with OAB" continued Mr. Julve.

About SVT-40776

SVT-40776 is a new potent and selective M3 muscarinic antagonist for the treatment of OAB with high bladder/salivary gland selectivity, long half life and low metabolic rate. Compared to oxybutynin, tolterodine, solifenacin and darifenacin, SVT-40776 is the most potent and selective M3 vs M2 yet developed. This profile is expected to give SVT-40776 an improved efficacy and tolerability, increasing the benefit/risk ratio.


SALVAT is an independent, privately owned, Spanish pharmaceutical group closely identified with technological innovation and strongly committed to R&D. In 2006 SALVAT's products were distributed in more than 30 countries all over the world in collaboration with well reputed pharmaceutical partners. SALVAT is working to strengthen its international presence by licensing its own developments, e.g. CETRAXAL eardrops (currently under US-FDA review) and by emphasizing collaborations regarding its pipeline products.


Cristina Viayna,

Business Development & Licensing

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sensitive detection of tumor cells in peripheral blood of carcinoma patients by a reverse transcription PCR method
2. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
3. Milwaukee takes another step in electronic patient data exchange
4. What patients want: A story of choice, clinical trials & evidence-based medicine
5. GE partner allows real-time access to patient data
6. Sun, TeraMedica solution aimed at doctor-patient relationship
7. Interview: Dr. William Yasnoff on patient-centric IT
8. Video game technology could improve physician-patient interactions
9. GE and Intermountain want to streamline nationwide patient data
10. Human factors and IT: Designing for patient safety
11. The challenges of maintaining patient privacy and delivering secure clinical information
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
(Date:11/24/2015)... ... 24, 2015 , ... The United States Golf Association (USGA) today announced Dr. ... Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in ...
(Date:11/24/2015)... VANCOUVER , Nov. 24, 2015 /CNW/ - iCo ... ICOTF), today reported financial results for the quarter ... are expressed in Canadian dollars and presented under ... the United States ," said Andrew ... "These advancements regarding iCo-008 are not only value ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... market report published by Transparency Market Research "Home Security Solutions ... and Forecast 2015 - 2022", the global home security solutions ... bn by 2022. The market is estimated to expand ... from 2015 to 2022. Rising security needs among customers ...
(Date:10/29/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that it has ... as one of only three finalists for a ... and Growing" category. The Tekne Awards honor Minnesota ... technology innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
Breaking Biology News(10 mins):